Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Mizuho to Buy

Mizuho upgraded shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) from a neutral rating to a buy rating in a research report report published on Tuesday morning, Marketbeat.com reports. The firm currently has $8.00 price objective on the stock, up from their prior price objective of $4.00. Several other research firms have also recently issued […]

Leave a Reply

Your email address will not be published.

Previous post Atlantic American (NASDAQ:AAME) Earns Hold Rating from Analysts at StockNews.com
Next post Affimed (NASDAQ:AFMD) Receives New Coverage from Analysts at StockNews.com